---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021080"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:25:41.314595+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma reports Q2 2022 net loss of $36.3M; cash of $787M funds into 2025

## Summary
- Revenue of $35.7M (vs $2.6M YoY), driven by $35.3M from concluding GSK hematological cancer research.
- Net loss GAAP $36.3M (vs $62.6M YoY); non-GAAP net loss $10.3M (vs $38.1M YoY).
- R&D expense $43.7M (vs $46.4M YoY); G&A expense $30.5M (vs $19.1M YoY) due to stock compensation.
- Cash, equivalents and marketable securities of $787.0M as of June 30, 2022, providing funding into 2025.
- Lead CAR T candidate LYL797 on track for initial clinical data in 2023; preclinical data presented at ASGCT.

## SEC filing metadata
- accession: 0001628280-22-021080
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/0001628280-22-021080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828022021080/lyel-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021080
- JSON: https://secwatch.observer/filing/0001628280-22-021080.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.